Lucid Diagnostics (LUCD) Q2 2025 Earnings Call August 13, 2025 08:30 AM ET Speaker0Good morning, and welcome toSpeaker1theSpeaker0Lucid Diagnostics Second Quarter twenty twenty five Business Update Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. Please note that this event is being recorded. I would now like to turn the conference over to Matt Reilly, Lucid Diagnostics' Senior Director of Investor Relations.Please ...

Exhibit 99.1 Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results Processed 2,756 EsoGuard tests and recognized 2Q25 revenue of $1.2 million, ending quarter with over $30 million in proforma cash and extending runway well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for EsoGuard to be held on September 4 Conference call and webcast to be held today, August 13, at ...

Core Insights - Lucid Diagnostics Inc. reported a revenue of $1.2 million for EsoGuard tests in Q2 2025, processing a total of 2,756 tests, and ended the quarter with over $30 million in proforma cash, extending its financial runway into 2026 [1][6][9] - A significant Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting regarding Medicare Local Coverage Determination (LCD) for EsoGuard is scheduled for September 4, 2025, which is seen as a critical step towards securing positive Medicare coverage [1][4][6] - The company has strengthened its balance sheet through a public offering, netting approximately $16.1 million in proceeds, and has initiated patient testing under a new commercial insurance coverage policy from Highmark Blue Cross Blue Shield [4][6][9] Business Highlights - The upcoming MolDx CAC meeting is viewed as a major milestone for Lucid, with expectations of strong support from medical experts for the clinical utility of EsoGuard [4] - Lucid has partnered with Hoag to launch a comprehensive EsoGuard testing program, enhancing access for at-risk patients [6] - A study sponsored by the National Cancer Institute (NCI) has shown that EsoGuard effectively detects esophageal precancer in patients without GERD symptoms, potentially increasing market opportunities by up to 70% [6] Financial Results - For the three months ended June 30, 2025, Lucid reported revenues of $1.2 million, with operating expenses of approximately $12.5 million, leading to a GAAP net loss of about $7.9 million or $(0.08) per share [9][10] - The non-GAAP adjusted loss for the same period was approximately $9.9 million or $(0.10) per share, reflecting the impact of stock-based compensation and other non-cash expenses [9][10] - Cash and cash equivalents stood at $31.1 million as of June 30, 2025, compared to $22.4 million at the end of 2024, indicating improved liquidity [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ LUCID DIAGNOSTICS INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 82-5488042 (State or Other Jurisdiction of (IRS Employer In ...

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4]. Upcoming Conference Call - Lucid Diagnostics will host a business update conference call and webcast on August 13, 2025, at 8:30 AM ET [1]. - The call will feature Lishan Aklog, M.D., the Chairman and CEO, providing a business update and overview of the company's operations and growth strategy [1]. - Dennis McGrath, the CFO, will discuss the company's second quarter 2025 financial results during the call [1]. Access Information - The webcast will be available on the investor relations section of the company's website [2]. - U.S.-based callers can access the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2]. - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [4]. - The test is performed on samples collected using the EsoCheck® Esophageal Cell Collection Device, which involves a brief, noninvasive office procedure [4].

Group 1 - Lucid Diagnostics Inc. announced a virtual public meeting on September 4, 2025, to discuss the reconsideration of Local Coverage Determination (LCD) L39256 for its EsoGuard® Esophageal DNA Test [1] - The meeting will involve Medicare Administrative Contractors and medical experts, focusing on the clinical literature related to esophageal precancer testing [2] - Lucid's CEO expressed optimism about the meeting's potential to lead to a positive Medicare coverage policy outcome, citing broad consensus in the GI community regarding the clinical utility of EsoGuard [2] Group 2 - Lucid Diagnostics is a commercial-stage company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) at risk of esophageal precancer [3] - The EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer through a noninvasive procedure, representing a significant advancement in cancer prevention tools [3]

Core Viewpoint - Lucid Diagnostics has partnered with Hoag to enhance access to EsoGuard esophageal precancer testing, aiming to combat the rising incidence of esophageal cancer in Orange County [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3]. - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients, performed through a non-invasive office procedure [3]. Partnership Details - Hoag has launched a comprehensive esophageal precancer testing program using Lucid's EsoGuard test, integrating it into its digestive health, primary care, and concierge medicine programs [1]. - The partnership is seen as a significant milestone in expanding access to EsoGuard within large healthcare systems, with expectations that it will serve as a model for other health systems [2]. Industry Context - The incidence of esophageal cancer has increased tenfold over the past four decades, highlighting the need for effective screening methods [2]. - The EsoGuard test offers a 3-minute non-endoscopic procedure aimed at identifying at-risk patients, which is critical for early intervention and potentially saving lives [2]. Hoag Overview - Hoag is a nonprofit regional healthcare delivery system in Orange County, California, recognized for its comprehensive personalized care and consisting of 1,800 physicians, 17 urgent care facilities, and two award-winning hospitals [5]. - It is ranked as the highest hospital in Orange County by U.S. News & World Report and is known for its specialized services in various health areas, including cancer and digestive health [5].

Financial Data and Key Metrics Changes - The meeting confirmed that a majority of shares were represented, constituting a quorum for the voting process [9] - The preliminary vote tallies indicated that management nominees were elected as directors and the issuance of common stock under the senior secured convertible notes was approved [20] Business Line Data and Key Metrics Changes - The proposal to approve the issuance of shares under the senior secured convertible notes was discussed, with a majority of shares voting in favor [14][16] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on maintaining compliance with Nasdaq listing rules and ensuring proper governance through the election of board members and the appointment of auditors [10][17] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during this meeting Other Important Information - The meeting was conducted via live webcast, allowing stockholders to vote and submit questions [3][4] - The final vote tallies will be disclosed in public filings with the SEC after the meeting [20] Q&A Session Summary - No questions were submitted during the meeting, and management indicated that they would respond to appropriate questions after the meeting [21]

Core Viewpoint - Lucid Diagnostics Inc. provided a business update and financial results for Q1 2025 during a conference call, highlighting key developments and future outlooks for the company [1][2][3]. Group 1: Company Overview - The conference call featured key participants including Matt Riley (Senior Director of Investor Relations), Dr. Lishan Aklog (Chairman and CEO), and Dennis McGrath (CFO) [1][3]. - The press release detailing the business update and financial results is accessible on Lucid's official website [3]. Group 2: Financial Results - Specific financial metrics and performance indicators were likely discussed during the call, although detailed figures are not provided in the available text [1][2][3].

Core Viewpoint - Lucid Diagnostics Inc. reported a quarterly loss of $0.16 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -77.78% [1][2] Financial Performance - The company posted revenues of $0.83 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 36.31%, compared to revenues of $1 million in the same quarter last year [2] - Over the last four quarters, Lucid Diagnostics has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Lucid Diagnostics shares have increased approximately 45.4% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $1.4 million, and for the current fiscal year, it is -$0.32 on revenues of $7 million [7] - The estimate revisions trend for Lucid Diagnostics is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Lucid Diagnostics belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]